Oncolytics Biotech (ONCY) Research & Development (2009 - 2026)
Oncolytics Biotech (ONCY) recorded Research & Development of $4.26 million in Q2 2026, up 122.4% from $1.92 million a year earlier.
Powered by 
Analysis
Oncolytics Biotech (ONCY) Research & Development (2009 - 2026) Analysis & Trends
On a TTM basis, Oncolytics Biotech's Research & Development came in at $24.94 million as of Jun 30, 2026, up 91.8% year-over-year; for FY2025, it was $13.31 million, down 13.8% from FY2024.
- Annual Research & Development has a five-year compound annual growth rate of 6.6% (FY2020 to FY2025).
- Across earlier years, Research & Development came in at $15.44 million in FY2024 (+17.7%), $13.13 million in FY2023 (+10.6%), $11.87 million in FY2022 (+15.1%) and $10.31 million in FY2021 (+6.7%).
- Quarterly Research & Development has ranged from $1.92 million in Q2 2025 to $13.3 million in Q4 2025 over the past five years.
- On a year-over-year basis, Research & Development rose in four of the last seven quarters, with growth averaging 53.5%.
- Peak year-over-year performance for Research & Development in the last five years was growth of 308.1% in Q4 2025, against a decline of 42.5% in Q2 2025 at the low end.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Oncolytics Biotech | 60.94 Mn | 32.05 Mn | - | 4.26 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.26 Mn |
| Sep 30, 2025 | 5.46 Mn |
| Jun 30, 2025 | 1.92 Mn |
| Mar 31, 2025 | 2.85 Mn |
| Dec 31, 2024 | 3.26 Mn |
| Sep 30, 2024 | 4.98 Mn |
| Jun 30, 2024 | 3.33 Mn |
| Mar 31, 2024 | 4.26 Mn |
| Dec 31, 2023 | 3.42 Mn |
| Sep 30, 2023 | 4.33 Mn |
| Jun 30, 2023 | 2.76 Mn |
| Mar 31, 2023 | 2.62 Mn |
| Dec 31, 2022 | 3.57 Mn |
| Sep 30, 2022 | 2.82 Mn |
| Jun 30, 2022 | 2.51 Mn |
| Mar 31, 2022 | 2.93 Mn |
| Dec 31, 2021 | 2.92 Mn |
| Sep 30, 2021 | 2.60 Mn |
| Jun 30, 2021 | 2.61 Mn |
| Mar 31, 2021 | 2.18 Mn |
API Access
Oncolytics Biotech Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=ONCY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "ONCY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=ONCY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();